Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „emtricitabine“
Suchtreffer
Begriffe & Kennungen
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 15 pathways. NNRTIs/Efavirenz Interaction not studied. Since use of two NNRTIs proved not beneficial in terms
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 16 decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect. Co-a
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 17 Cmax: ↔ Cmin: ↔
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 18 Rifabutin/Efavirenz Rifabutin: The daily dose of rifabutin should (300 mg q.d./600 mg q.d.) AUC: ↓ 38% (↓ 2
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 19 Posaconazole/Efavirenz Posaconazole: Concomitant use of posaconazole (-/400 mg q.d.) AUC: ↓ 50% and Cmax: ↓
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 20 Carbamazepine/Efavirenz Carbamazepine: No dose recommendation can be (400 mg q.d./600 mg q.d.) AUC: ↓ 27% (
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 21 Cmax: ↓ 29% (↓ 15 to ↓ 40) disoproxil, sertraline dose Cmin: ↓ 46% (↓ 31 to ↓ 58) increases should be guide
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 22 Efavirenz: AUC: ↑ 11% (↑ 5 to ↑ 18) Cmax: ↑ 16% (↑ 6 to ↑ 26) Cmin: ↑ 13% (↑ 1 to ↑ 26) (CYP3A4 induction)
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 23 Cmax: ↓ 51% (↓ 32 to ↓ 58) disoproxil (refer to the Summary of Product Characteristics for Total active HMG
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 24 Similar results were found by other investigators, although the MPA plasma levels were more variable in the
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 25 AUC: ↔ Cmax: ↔ Cmin: ↔ Methadone/Emtricitabine Interaction not studied. Buprenorphine/naloxone/Efavirenz Bu
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 9 efavirenz/emtricitabine/tenofovir disoproxil. Interaction studies with these agents have only been performed
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · Antimycobacterials
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · As a fixed combination, efavirenz/emtricitabine/tenofovir disoproxil should not be administered concomitantly
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · As efavirenz/emtricitabine/tenofovir disoproxil contains efavirenz, emtricitabine and tenofovir disoproxil, an
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · Atazanavir/ritonavir Insufficient data are available to make a dosing recommendation for atazanavir/ritonavir
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · Atazanavir/ritonavir/Efavirenz Atazanavir (pm): (400 mg q.d./200 mg q.d./600 mg AUC: ↔*/** (↓ 10% to ↑ 26%) q.
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · Cannabinoid test interaction
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · Co-administration of efavirenz with atorvastatin, pravastatin, or simvastatin did not affect efavirenz AUC or
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · Co-administration of higher doses of either efavirenz or carbamazepine has not been studied. Carbamazepine/Emt
Eintrag öffnen